- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT04310007
Tester tillegget av pillen kjemoterapi, Cabozantinib, til standard immunterapi Nivolumab sammenlignet med standard kjemoterapi for ikke-småcellet lungekreft
En randomisert fase II-studie av Cabozantinib og Cabozantinib Plus Nivolumab versus standard kjemoterapi hos pasienter med tidligere behandlet ikke-plateepitel NSCLC
This phase II trial compares cabozantinib alone and the combination of cabozantinib and nivolumab to standard chemotherapy in the treatment of patients with non-squamous non-small cell lung cancer (NSCLC). Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Ramucirumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as docetaxel, gemcitabine hydrochloride, paclitaxel, and nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving cabozantinib alone or in combination with nivolumab may be more effective than standard chemotherapy in treating patients with non-small cell lung cancer.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
PRIMARY OBJECTIVE:
I. To determine whether cabozantinib alone, or the combination of nivolumab and cabozantinib, as compared to standard chemotherapy alone, extends progression-free survival (PFS) for this patient population with non squamous NSCLC.
SECONDARY OBJECTIVES:
I. To determine the overall survival for each arm of the trial. II. To evaluate the best overall radiographic response rate for each arm of the trial.
III. To evaluate and describe the toxicity profile of monotherapy with cabozantinib, and the combination of nivolumab and cabozantinib in this patient population with non-squamous NSCLC.
EXPLORATORY IMAGING OBJECTIVES:
I. To describe time point tumor response assessment, overall best response, progression-free survival and overall survival using the conventional Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria and the exploratory revised CHOI criteria with all measurements performed by the central review.
II. To compare the progression-free survival using the RECIST1.1 imaging response assessment measurements by site study personnel to those performed by central review.
EXPLORATORY CORRELATIVE OBJECTIVE:
I. To perform correlative biomarker research on tissue and blood biospecimens collected within this trial.
OUTLINE:
STEP 1: Patients are randomized to 1 of 3 arms.
ARM A: Patients receive cabozantinib S-malate orally (PO) once daily (QD). Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients may continue to receive therapy after investigator-assessed RECIST 1.1 defined progression, including stable clinical and performance status and have potential for continued clinical benefit.
ARM B: Patients receive cabozantinib S-malate PO QD and nivolumab intravenously (IV) over 30 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients may continue to receive therapy after investigator-assessed RECIST 1.1 defined progression, including stable clinical and performance status and have potential for continued clinical benefit.
ARM C: Patients receive ramucirumab IV over 30-60 minutes and docetaxel IV over 1 hour on day 1, or docetaxel IV over 1 hour on days 1 and 8, or gemcitabine hydrochloride IV on days 1 and 8, or paclitaxel IV over 3 hours on day 1, or nab-paclitaxel IV over 30 minutes on days 1 and 8. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity and at the discretion of the treating physician.
STEP 2: Patients in Arm C experiencing disease progression are assigned to Arm Z.
ARM Z: Patients receive cabozantinib S-malate PO QD and nivolumab IV over 30 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients may continue to receive therapy after investigator-assessed RECIST 1.1 defined progression, including stable clinical and performance status and have potential for continued clinical benefit.
Patients in all arms undergo echocardiogram (ECHO) as clinically indicated, computed tomography (CT) throughout the trial, and collection of blood on study.
After the completion of study treatment, patients are followed up every 3 months for up to 3 years.
Studietype
Registrering (Antatt)
Fase
- Fase 2
Kontakter og plasseringer
Studiesteder
-
-
Alabama
-
Birmingham, Alabama, Forente stater, 35233
- Veterans Administration Medical Center - Birmingham
-
-
Alaska
-
Anchorage, Alaska, Forente stater, 98508
- Anchorage Associates in Radiation Medicine
-
Anchorage, Alaska, Forente stater, 99508
- Alaska Breast Care and Surgery LLC
-
Anchorage, Alaska, Forente stater, 99508
- Alaska Oncology and Hematology LLC
-
Anchorage, Alaska, Forente stater, 99508
- Alaska Women's Cancer Care
-
Anchorage, Alaska, Forente stater, 99508
- Anchorage Oncology Centre
-
Anchorage, Alaska, Forente stater, 99508
- Katmai Oncology Group
-
Anchorage, Alaska, Forente stater, 99508
- Providence Alaska Medical Center
-
Anchorage, Alaska, Forente stater, 99504
- Anchorage Radiation Therapy Center
-
Fairbanks, Alaska, Forente stater, 99701
- Fairbanks Memorial Hospital
-
-
Arizona
-
Goodyear, Arizona, Forente stater, 85338
- CTCA at Western Regional Medical Center
-
Kingman, Arizona, Forente stater, 86401
- Kingman Regional Medical Center
-
Phoenix, Arizona, Forente stater, 85004
- Cancer Center at Saint Joseph's
-
Tucson, Arizona, Forente stater, 85719
- Banner University Medical Center - Tucson
-
Tucson, Arizona, Forente stater, 85719
- University of Arizona Cancer Center-North Campus
-
-
Arkansas
-
Fort Smith, Arkansas, Forente stater, 72903
- Mercy Hospital Fort Smith
-
Hot Springs, Arkansas, Forente stater, 71913
- CHI Saint Vincent Cancer Center Hot Springs
-
-
California
-
Arroyo Grande, California, Forente stater, 93420
- PCR Oncology
-
Arroyo Grande, California, Forente stater, 93420
- Mission Hope Medical Oncology - Arroyo Grande
-
Burbank, California, Forente stater, 91505
- Providence Saint Joseph Medical Center/Disney Family Cancer Center
-
Carmichael, California, Forente stater, 95608
- Mercy San Juan Medical Center
-
Carmichael, California, Forente stater, 95608
- Mercy Cancer Center - Carmichael
-
Elk Grove, California, Forente stater, 95758
- Mercy Cancer Center - Elk Grove
-
Fremont, California, Forente stater, 94538
- Washington Health
-
Marysville, California, Forente stater, 95901
- Fremont - Rideout Cancer Center
-
Orange, California, Forente stater, 92868
- Saint Joseph Hospital - Orange
-
Palo Alto, California, Forente stater, 94304
- Stanford Cancer Institute Palo Alto
-
Rocklin, California, Forente stater, 95765
- Mercy Cancer Center - Rocklin
-
Sacramento, California, Forente stater, 95817
- University of California Davis Comprehensive Cancer Center
-
Sacramento, California, Forente stater, 95816
- Mercy Cancer Center - Sacramento
-
San Luis Obispo, California, Forente stater, 93401
- Pacific Central Coast Health Center-San Luis Obispo
-
Santa Maria, California, Forente stater, 93444
- Mission Hope Medical Oncology - Santa Maria
-
Woodland, California, Forente stater, 95695
- Woodland Memorial Hospital
-
-
Colorado
-
Aurora, Colorado, Forente stater, 80012
- Rocky Mountain Cancer Centers-Aurora
-
Aurora, Colorado, Forente stater, 80012
- The Medical Center of Aurora
-
Boulder, Colorado, Forente stater, 80303
- Boulder Community Foothills Hospital
-
Boulder, Colorado, Forente stater, 80304
- Rocky Mountain Cancer Centers-Boulder
-
Centennial, Colorado, Forente stater, 80112
- Rocky Mountain Cancer Centers - Centennial
-
Colorado Springs, Colorado, Forente stater, 80907
- Penrose-Saint Francis Healthcare
-
Colorado Springs, Colorado, Forente stater, 80907
- Rocky Mountain Cancer Centers-Penrose
-
Colorado Springs, Colorado, Forente stater, 80923
- Saint Francis Cancer Center
-
Denver, Colorado, Forente stater, 80218
- Presbyterian - Saint Lukes Medical Center - Health One
-
Denver, Colorado, Forente stater, 80220
- Rose Medical Center
-
Denver, Colorado, Forente stater, 80218
- Rocky Mountain Cancer Centers-Midtown
-
Denver, Colorado, Forente stater, 80220
- Rocky Mountain Cancer Centers-Rose
-
Denver, Colorado, Forente stater, 80218
- Colorado Blood Cancer Institute
-
Denver, Colorado, Forente stater, 80204
- Cancer Center of Colorado at Sloan's Lake
-
Denver, Colorado, Forente stater, 80209
- The Women's Imaging Center
-
Denver, Colorado, Forente stater, 80206
- National Jewish Health-Main Campus
-
Denver, Colorado, Forente stater, 80220
- Western Surgical Care
-
Denver, Colorado, Forente stater, 80218
- Saint Joseph Hospital - Cancer Centers of Colorado
-
Denver, Colorado, Forente stater, 80210
- AdventHealth Porter
-
Durango, Colorado, Forente stater, 81301
- Mercy Medical Center
-
Durango, Colorado, Forente stater, 81301
- CommonSpirit Cancer Center Mercy
-
Englewood, Colorado, Forente stater, 80113
- Mountain Blue Cancer Care Center - Swedish
-
Englewood, Colorado, Forente stater, 80113
- Swedish Medical Center
-
Englewood, Colorado, Forente stater, 80113
- Rocky Mountain Cancer Centers - Swedish
-
Englewood, Colorado, Forente stater, 80113
- The Melanoma and Skin Cancer Institute
-
Fort Collins, Colorado, Forente stater, 80524
- Poudre Valley Hospital
-
Fort Collins, Colorado, Forente stater, 80528
- Cancer Care and Hematology-Fort Collins
-
Golden, Colorado, Forente stater, 80401
- National Jewish Health-Western Hematology Oncology
-
Grand Junction, Colorado, Forente stater, 81501
- Saint Mary's Hospital and Regional Medical Center
-
Greeley, Colorado, Forente stater, 80631
- UCHealth Greeley Hospital
-
Greeley, Colorado, Forente stater, 80631
- Banner North Colorado Medical Center
-
Highlands Ranch, Colorado, Forente stater, 80129
- UCHealth Highlands Ranch Hospital
-
Lafayette, Colorado, Forente stater, 80026
- Good Samaritan Hospital - Cancer Centers of Colorado
-
Lakewood, Colorado, Forente stater, 80228
- Rocky Mountain Cancer Centers-Lakewood
-
Lakewood, Colorado, Forente stater, 80228
- CommonSpirit Saint Anthony Hospital Cancer Center
-
Littleton, Colorado, Forente stater, 80120
- Rocky Mountain Cancer Centers-Littleton
-
Littleton, Colorado, Forente stater, 80122
- AdventHealth Littleton
-
Lone Tree, Colorado, Forente stater, 80124
- Sky Ridge Medical Center
-
Lone Tree, Colorado, Forente stater, 80124
- Rocky Mountain Cancer Centers-Sky Ridge
-
Longmont, Colorado, Forente stater, 80501
- Longmont United Hospital
-
Longmont, Colorado, Forente stater, 80501
- Rocky Mountain Cancer Centers-Longmont
-
Loveland, Colorado, Forente stater, 80538
- Medical Center of the Rockies
-
Loveland, Colorado, Forente stater, 80539
- Banner North Colorado Medical Center - Loveland Campus
-
Parker, Colorado, Forente stater, 80138
- AdventHealth Parker
-
Pueblo, Colorado, Forente stater, 81004
- Saint Mary Corwin Medical Center
-
Thornton, Colorado, Forente stater, 80260
- Rocky Mountain Cancer Centers-Thornton
-
Thornton, Colorado, Forente stater, 80260
- National Jewish Health-Northern Hematology Oncology
-
-
Connecticut
-
West Haven, Connecticut, Forente stater, 06516
- Veterans Affairs Connecticut Healthcare System-West Haven Campus
-
-
Florida
-
Aventura, Florida, Forente stater, 33180
- Mount Sinai Comprehensive Cancer Center at Aventura
-
Fort Lauderdale, Florida, Forente stater, 33308
- Holy Cross Hospital
-
Miami Beach, Florida, Forente stater, 33140
- Mount Sinai Medical Center
-
-
Georgia
-
Atlanta, Georgia, Forente stater, 30308
- Emory University Hospital Midtown
-
Atlanta, Georgia, Forente stater, 30322
- Emory University Hospital/Winship Cancer Institute
-
Savannah, Georgia, Forente stater, 31405
- Lewis Cancer and Research Pavilion at Saint Joseph's/Candler
-
-
Idaho
-
Boise, Idaho, Forente stater, 83706
- Saint Alphonsus Cancer Care Center-Boise
-
Boise, Idaho, Forente stater, 83712
- Saint Luke's Cancer Institute - Boise
-
Caldwell, Idaho, Forente stater, 83605
- Saint Alphonsus Cancer Care Center-Caldwell
-
Coeur d'Alene, Idaho, Forente stater, 83814
- Kootenai Health - Coeur d'Alene
-
Emmett, Idaho, Forente stater, 83617
- Walter Knox Memorial Hospital
-
Fruitland, Idaho, Forente stater, 83619
- Saint Luke's Cancer Institute - Fruitland
-
Meridian, Idaho, Forente stater, 83642
- Idaho Urologic Institute-Meridian
-
Meridian, Idaho, Forente stater, 83642
- Saint Luke's Cancer Institute - Meridian
-
Nampa, Idaho, Forente stater, 83687
- Saint Alphonsus Cancer Care Center-Nampa
-
Nampa, Idaho, Forente stater, 83687
- Saint Luke's Cancer Institute - Nampa
-
Post Falls, Idaho, Forente stater, 83854
- Kootenai Clinic Cancer Services - Post Falls
-
Sandpoint, Idaho, Forente stater, 83864
- Kootenai Clinic Cancer Services - Sandpoint
-
Twin Falls, Idaho, Forente stater, 83301
- Saint Luke's Cancer Institute - Twin Falls
-
-
Illinois
-
Alton, Illinois, Forente stater, 62002
- OSF Saint Anthony's Health Center
-
Aurora, Illinois, Forente stater, 60504
- Rush-Copley Medical Center
-
Barrington, Illinois, Forente stater, 60010
- Advocate Good Shepherd Hospital
-
Bloomington, Illinois, Forente stater, 61704
- Illinois CancerCare-Bloomington
-
Canton, Illinois, Forente stater, 61520
- Illinois CancerCare-Canton
-
Carbondale, Illinois, Forente stater, 62902
- Memorial Hospital of Carbondale
-
Carterville, Illinois, Forente stater, 62918
- SIH Cancer Institute
-
Carthage, Illinois, Forente stater, 62321
- Illinois CancerCare-Carthage
-
Centralia, Illinois, Forente stater, 62801
- Centralia Oncology Clinic
-
Centralia, Illinois, Forente stater, 62801
- Saint Mary's Hospital
-
Chicago, Illinois, Forente stater, 60612
- University of Illinois
-
Chicago, Illinois, Forente stater, 60657
- Advocate Illinois Masonic Medical Center
-
Crystal Lake, Illinois, Forente stater, 60014
- AMG Crystal Lake - Oncology
-
Danville, Illinois, Forente stater, 61832
- Carle at The Riverfront
-
Decatur, Illinois, Forente stater, 62526
- Decatur Memorial Hospital
-
Decatur, Illinois, Forente stater, 62526
- Cancer Care Specialists of Illinois - Decatur
-
Dixon, Illinois, Forente stater, 61021
- Illinois CancerCare-Dixon
-
Downers Grove, Illinois, Forente stater, 60515
- Advocate Good Samaritan Hospital
-
Effingham, Illinois, Forente stater, 62401
- Crossroads Cancer Center
-
Effingham, Illinois, Forente stater, 62401
- Carle Physician Group-Effingham
-
Elgin, Illinois, Forente stater, 60123
- Advocate Sherman Hospital
-
Eureka, Illinois, Forente stater, 61530
- Illinois CancerCare-Eureka
-
Galesburg, Illinois, Forente stater, 61401
- Western Illinois Cancer Treatment Center
-
Galesburg, Illinois, Forente stater, 61401
- Illinois CancerCare-Galesburg
-
Hazel Crest, Illinois, Forente stater, 60429
- Advocate South Suburban Hospital
-
Hines, Illinois, Forente stater, 60141
- Edward Hines Jr VA Hospital
-
Kewanee, Illinois, Forente stater, 61443
- Illinois CancerCare-Kewanee Clinic
-
Libertyville, Illinois, Forente stater, 60048
- Condell Memorial Hospital
-
Libertyville, Illinois, Forente stater, 60048
- AMG Libertyville - Oncology
-
Macomb, Illinois, Forente stater, 61455
- Illinois CancerCare-Macomb
-
Mattoon, Illinois, Forente stater, 61938
- Carle Physician Group-Mattoon/Charleston
-
Mount Vernon, Illinois, Forente stater, 62864
- SSM Health Good Samaritan
-
O'Fallon, Illinois, Forente stater, 62269
- Cancer Care Center of O'Fallon
-
Oak Lawn, Illinois, Forente stater, 60453-2699
- Advocate Christ Medical Center
-
Ottawa, Illinois, Forente stater, 61350
- Illinois CancerCare-Ottawa Clinic
-
Park Ridge, Illinois, Forente stater, 60068
- Advocate Lutheran General Hospital
-
Pekin, Illinois, Forente stater, 61554
- Illinois CancerCare-Pekin
-
Peoria, Illinois, Forente stater, 61636
- Methodist Medical Center of Illinois
-
Peoria, Illinois, Forente stater, 61615
- Illinois CancerCare-Peoria
-
Peru, Illinois, Forente stater, 61354
- Illinois CancerCare-Peru
-
Peru, Illinois, Forente stater, 61354
- Valley Radiation Oncology
-
Princeton, Illinois, Forente stater, 61356
- Illinois CancerCare-Princeton
-
Rockford, Illinois, Forente stater, 61114
- UW Health Carbone Cancer Center Rockford
-
Springfield, Illinois, Forente stater, 62702
- Southern Illinois University School of Medicine
-
Springfield, Illinois, Forente stater, 62702
- Springfield Clinic
-
Springfield, Illinois, Forente stater, 62781
- Springfield Memorial Hospital
-
Swansea, Illinois, Forente stater, 62226
- Southwest Illinois Health Services LLP
-
Urbana, Illinois, Forente stater, 61801
- Carle Cancer Center
-
Urbana, Illinois, Forente stater, 61801
- The Carle Foundation Hospital
-
Washington, Illinois, Forente stater, 61571
- Illinois CancerCare - Washington
-
Yorkville, Illinois, Forente stater, 60560
- Rush-Copley Healthcare Center
-
-
Indiana
-
Richmond, Indiana, Forente stater, 47374
- Reid Health
-
South Bend, Indiana, Forente stater, 46601
- Memorial Hospital of South Bend
-
-
Iowa
-
Ames, Iowa, Forente stater, 50010
- Mary Greeley Medical Center
-
Ames, Iowa, Forente stater, 50010
- McFarland Clinic - Ames
-
Bettendorf, Iowa, Forente stater, 52722
- University of Iowa Healthcare Cancer Services Quad Cities
-
Boone, Iowa, Forente stater, 50036
- McFarland Clinic - Boone
-
Carroll, Iowa, Forente stater, 51401
- Saint Anthony Regional Hospital
-
Clive, Iowa, Forente stater, 50325
- Mercy Cancer Center-West Lakes
-
Clive, Iowa, Forente stater, 50325
- UI Health Care Mission Cancer and Blood - West Des Moines Clinic
-
Council Bluffs, Iowa, Forente stater, 51503
- Alegent Health Mercy Hospital
-
Council Bluffs, Iowa, Forente stater, 51503
- Heartland Oncology and Hematology LLP
-
Council Bluffs, Iowa, Forente stater, 51503
- Methodist Jennie Edmundson Hospital
-
Creston, Iowa, Forente stater, 50801
- Greater Regional Medical Center
-
Des Moines, Iowa, Forente stater, 50309
- Iowa Methodist Medical Center
-
Des Moines, Iowa, Forente stater, 50314
- Mercy Medical Center - Des Moines
-
Des Moines, Iowa, Forente stater, 50314
- Broadlawns Medical Center
-
Des Moines, Iowa, Forente stater, 50316
- Iowa Lutheran Hospital
-
Des Moines, Iowa, Forente stater, 50309
- UI Health Care Mission Cancer and Blood - Des Moines Clinic
-
Des Moines, Iowa, Forente stater, 50314
- UI Health Care Mission Cancer and Blood - Laurel Clinic
-
Fort Dodge, Iowa, Forente stater, 50501
- McFarland Clinic - Trinity Cancer Center
-
Fort Dodge, Iowa, Forente stater, 50501
- UI Healthcare Mission Cancer and Blood - Fort Dodge
-
Iowa City, Iowa, Forente stater, 52242
- University of Iowa/Holden Comprehensive Cancer Center
-
Jefferson, Iowa, Forente stater, 50129
- McFarland Clinic - Jefferson
-
Marshalltown, Iowa, Forente stater, 50158
- McFarland Clinic - Marshalltown
-
West Des Moines, Iowa, Forente stater, 50266-7700
- Methodist West Hospital
-
West Des Moines, Iowa, Forente stater, 50266
- Mercy Medical Center-West Lakes
-
-
Kansas
-
Garden City, Kansas, Forente stater, 67846
- Central Care Cancer Center - Garden City
-
Great Bend, Kansas, Forente stater, 67530
- Central Care Cancer Center - Great Bend
-
Hays, Kansas, Forente stater, 67601
- HaysMed
-
Lawrence, Kansas, Forente stater, 66044
- Lawrence Memorial Hospital
-
Olathe, Kansas, Forente stater, 66061
- The University of Kansas Cancer Center - Olathe
-
Overland Park, Kansas, Forente stater, 66213
- Saint Luke's South Hospital
-
Pittsburg, Kansas, Forente stater, 66762
- Freeman Physician Group of Pittsburg
-
Pittsburg, Kansas, Forente stater, 66762
- Mercy Hospital Pittsburg
-
Salina, Kansas, Forente stater, 67401
- Salina Regional Health Center
-
Topeka, Kansas, Forente stater, 66606
- University of Kansas Health System Saint Francis Campus
-
-
Kentucky
-
Bardstown, Kentucky, Forente stater, 40004
- CommonSpirit Saint Joseph Hospital - Bardstown
-
Corbin, Kentucky, Forente stater, 40701
- Commonwealth Cancer Center-Corbin
-
Lexington, Kentucky, Forente stater, 40504
- Saint Joseph Radiation Oncology Resource Center
-
Lexington, Kentucky, Forente stater, 40509
- CommonSpirit Saint Joseph Medical Center - East Lexington
-
Lexington, Kentucky, Forente stater, 40504
- CommonSpirit Saint Joseph Hospital - Lexington
-
London, Kentucky, Forente stater, 40741
- CommonSpirit Saint Joseph Hospital London
-
Louisville, Kentucky, Forente stater, 40202
- Jewish Hospital
-
Louisville, Kentucky, Forente stater, 40245
- UofL Health Medical Center Northeast
-
Louisville, Kentucky, Forente stater, 40215
- Saints Mary and Elizabeth Hospital
-
Mount Sterling, Kentucky, Forente stater, 40353
- CommonSpirit Saint Joseph Hospital Mount Sterling
-
Owensboro, Kentucky, Forente stater, 42303
- Owensboro Health Mitchell Memorial Cancer Center
-
Paducah, Kentucky, Forente stater, 42003
- Mercy Health - Paducah Cancer Center
-
Shepherdsville, Kentucky, Forente stater, 40165
- Jewish Hospital Medical Center South
-
-
Louisiana
-
Baton Rouge, Louisiana, Forente stater, 70805
- LSU Health Baton Rouge-North Clinic
-
Baton Rouge, Louisiana, Forente stater, 70809
- Louisiana Hematology Oncology Associates LLC
-
Baton Rouge, Louisiana, Forente stater, 70809
- Mary Bird Perkins Cancer Center
-
Baton Rouge, Louisiana, Forente stater, 70808
- Our Lady of The Lake
-
Baton Rouge, Louisiana, Forente stater, 70808
- Our Lady of the Lake Physician Group
-
Covington, Louisiana, Forente stater, 70433
- Northshore Oncology Associates-Covington
-
Houma, Louisiana, Forente stater, 70360
- Terrebonne General Medical Center
-
-
Maine
-
Augusta, Maine, Forente stater, 04330
- Harold Alfond Center for Cancer Care
-
Biddeford, Maine, Forente stater, 04005
- MaineHealth Maine Medical Center - Biddeford
-
Sanford, Maine, Forente stater, 04073
- MaineHealth Cancer Care and IV Therapy - Sanford
-
South Portland, Maine, Forente stater, 04106
- MaineHealth Cancer Care and IV Therapy - South Portland
-
-
Maryland
-
Baltimore, Maryland, Forente stater, 21229
- Saint Agnes Hospital
-
-
Massachusetts
-
Boston, Massachusetts, Forente stater, 02118
- Boston Medical Center
-
Worcester, Massachusetts, Forente stater, 01655
- UMass Memorial Medical Center - University Campus
-
-
Michigan
-
Adrian, Michigan, Forente stater, 49221
- Hickman Cancer Center
-
Ann Arbor, Michigan, Forente stater, 48106
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
-
Battle Creek, Michigan, Forente stater, 49017
- Bronson Battle Creek
-
Brighton, Michigan, Forente stater, 48114
- Trinity Health IHA Medical Group Hematology Oncology - Brighton
-
Brighton, Michigan, Forente stater, 48114
- Trinity Health Medical Center - Brighton
-
Canton, Michigan, Forente stater, 48188
- Trinity Health IHA Medical Group Hematology Oncology - Canton
-
Canton, Michigan, Forente stater, 48188
- Trinity Health Medical Center - Canton
-
Caro, Michigan, Forente stater, 48723
- Caro Cancer Center
-
Chelsea, Michigan, Forente stater, 48118
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
-
Chelsea, Michigan, Forente stater, 48118
- Chelsea Hospital
-
Clarkston, Michigan, Forente stater, 48346
- Hematology Oncology Consultants-Clarkston
-
Clarkston, Michigan, Forente stater, 48346
- Newland Medical Associates-Clarkston
-
Detroit, Michigan, Forente stater, 48236
- Henry Ford Health Saint John Hospital
-
East China Township, Michigan, Forente stater, 48054
- Henry Ford River District Hospital
-
Flint, Michigan, Forente stater, 48503
- Hurley Medical Center
-
Flint, Michigan, Forente stater, 48503
- Genesee Hematology Oncology PC
-
Flint, Michigan, Forente stater, 48503
- Genesys Hurley Cancer Institute
-
Flint, Michigan, Forente stater, 48503
- Cancer Hematology Centers - Flint
-
Grand Rapids, Michigan, Forente stater, 49503
- Trinity Health Grand Rapids Hospital
-
Grand Rapids, Michigan, Forente stater, 49503
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital
-
Grand Rapids, Michigan, Forente stater, 49503
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital
-
Grosse Pointe Woods, Michigan, Forente stater, 48236
- Henry Ford Saint John Hospital - Academic
-
Grosse Pointe Woods, Michigan, Forente stater, 48236
- Henry Ford Saint John Hospital - Breast
-
Grosse Pointe Woods, Michigan, Forente stater, 48236
- Henry Ford Saint John Hospital - Van Elslander
-
Kalamazoo, Michigan, Forente stater, 49007
- West Michigan Cancer Center
-
Kalamazoo, Michigan, Forente stater, 49007
- Bronson Methodist Hospital
-
Kalamazoo, Michigan, Forente stater, 49009
- Beacon Kalamazoo Cancer Center
-
Kalamazoo, Michigan, Forente stater, 49048
- Beacon Kalamazoo
-
Lansing, Michigan, Forente stater, 48912
- University of Michigan Health - Sparrow Lansing
-
Livonia, Michigan, Forente stater, 48154
- Trinity Health Saint Mary Mercy Livonia Hospital
-
Livonia, Michigan, Forente stater, 48154
- Hope Cancer Clinic
-
Macomb, Michigan, Forente stater, 48044
- Henry Ford Warren Hospital - Breast Macomb
-
Macomb, Michigan, Forente stater, 48044
- Henry Ford Saint John Hospital - Macomb Medical
-
Marlette, Michigan, Forente stater, 48453
- Saint Mary's Oncology/Hematology Associates of Marlette
-
Monroe, Michigan, Forente stater, 48162
- Toledo Clinic Cancer Centers-Monroe
-
Muskegon, Michigan, Forente stater, 49444
- Trinity Health Muskegon Hospital
-
Niles, Michigan, Forente stater, 49120
- Corewell Health Lakeland Hospitals - Niles Hospital
-
Norton Shores, Michigan, Forente stater, 49444
- Cancer and Hematology Centers of Western Michigan - Norton Shores
-
Novi, Michigan, Forente stater, 48374
- Henry Ford Health Providence Novi Hospital
-
Pontiac, Michigan, Forente stater, 48341
- Hope Cancer Center
-
Pontiac, Michigan, Forente stater, 48341
- Trinity Health Saint Joseph Mercy Oakland Hospital
-
Pontiac, Michigan, Forente stater, 48341
- Michigan Healthcare Professionals Pontiac
-
Pontiac, Michigan, Forente stater, 48341
- Trinity Health IHA Medical Group-Alice Gustafson Center
-
Reed City, Michigan, Forente stater, 49677
- Corewell Health Reed City Hospital
-
Rochester Hills, Michigan, Forente stater, 48309
- Henry Ford Rochester Hospital
-
Saginaw, Michigan, Forente stater, 48604
- Oncology Hematology Associates of Saginaw Valley PC
-
Saginaw, Michigan, Forente stater, 48601
- MyMichigan Medical Center Saginaw
-
Saint Joseph, Michigan, Forente stater, 49085
- Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center
-
Saint Joseph, Michigan, Forente stater, 49085
- Corewell Health Lakeland Hospitals - Saint Joseph Hospital
-
Southfield, Michigan, Forente stater, 48075
- Henry Ford Health Providence Southfield Hospital
-
Sterling Heights, Michigan, Forente stater, 48312
- Bhadresh Nayak MD PC-Sterling Heights
-
Tawas City, Michigan, Forente stater, 48764
- MyMichigan Medical Center Tawas
-
Traverse City, Michigan, Forente stater, 49684
- Munson Medical Center
-
Warren, Michigan, Forente stater, 48088
- Advanced Breast Care Center PLLC
-
Warren, Michigan, Forente stater, 48093
- Macomb Hematology Oncology PC
-
Warren, Michigan, Forente stater, 48093
- Henry Ford Madison Heights Hospital - Breast
-
Warren, Michigan, Forente stater, 48093
- Henry Ford Health Warren Hospital
-
Warren, Michigan, Forente stater, 48093
- Henry Ford Warren Hospital - GLCMS
-
West Branch, Michigan, Forente stater, 48661
- Saint Mary's Oncology/Hematology Associates of West Branch
-
Wyoming, Michigan, Forente stater, 49519
- University of Michigan Health - West
-
Ypsilanti, Michigan, Forente stater, 48197
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
-
Ypsilanti, Michigan, Forente stater, 48106
- Huron Gastroenterology PC
-
-
Minnesota
-
Aitkin, Minnesota, Forente stater, 56431
- Riverwood Healthcare Center
-
Baxter, Minnesota, Forente stater, 56425
- Essentia Health - Baxter Clinic
-
Brainerd, Minnesota, Forente stater, 56401
- Essentia Health Saint Joseph's Medical Center
-
Burnsville, Minnesota, Forente stater, 55337
- Fairview Ridges Hospital
-
Burnsville, Minnesota, Forente stater, 55337
- Minnesota Oncology - Burnsville
-
Cambridge, Minnesota, Forente stater, 55008
- Cambridge Medical Center
-
Coon Rapids, Minnesota, Forente stater, 55433
- Mercy Hospital
-
Deer River, Minnesota, Forente stater, 56636
- Essentia Health - Deer River Clinic
-
Detroit Lakes, Minnesota, Forente stater, 56501
- Essentia Health Saint Mary's - Detroit Lakes Clinic
-
Duluth, Minnesota, Forente stater, 55805
- Essentia Health Cancer Center
-
Duluth, Minnesota, Forente stater, 55805
- Essentia Health Saint Mary's Medical Center
-
Duluth, Minnesota, Forente stater, 55805
- Miller-Dwan Hospital
-
Edina, Minnesota, Forente stater, 55435
- Fairview Southdale Hospital
-
Ely, Minnesota, Forente stater, 55731
- Essentia Health - Ely Clinic
-
Fergus Falls, Minnesota, Forente stater, 56537
- Lake Region Healthcare Corporation-Cancer Care
-
Fosston, Minnesota, Forente stater, 56542
- Essentia Health - Fosston
-
Fridley, Minnesota, Forente stater, 55432
- Unity Hospital
-
Hibbing, Minnesota, Forente stater, 55746
- Essentia Health Hibbing Clinic
-
International Falls, Minnesota, Forente stater, 56649
- Essentia Health - International Falls Clinic
-
Maple Grove, Minnesota, Forente stater, 55369
- Fairview Clinics and Surgery Center Maple Grove
-
Maplewood, Minnesota, Forente stater, 55109
- Saint John's Hospital - Healtheast
-
Maplewood, Minnesota, Forente stater, 55109
- Minnesota Oncology Hematology PA-Maplewood
-
Minneapolis, Minnesota, Forente stater, 55415
- Hennepin County Medical Center
-
Minneapolis, Minnesota, Forente stater, 55407
- Abbott-Northwestern Hospital
-
Minneapolis, Minnesota, Forente stater, 55454
- Health Partners Inc
-
Monticello, Minnesota, Forente stater, 55362
- Monticello Cancer Center
-
Moose Lake, Minnesota, Forente stater, 55767
- Essentia Health - Moose Lake Clinic
-
New Ulm, Minnesota, Forente stater, 56073
- New Ulm Medical Center
-
Park Rapids, Minnesota, Forente stater, 56470
- Essentia Health - Park Rapids
-
Princeton, Minnesota, Forente stater, 55371
- Fairview Northland Medical Center
-
Robbinsdale, Minnesota, Forente stater, 55422
- North Memorial Medical Health Center
-
Saint Louis Park, Minnesota, Forente stater, 55416
- Park Nicollet Clinic - Saint Louis Park
-
Saint Paul, Minnesota, Forente stater, 55101
- Regions Hospital
-
Saint Paul, Minnesota, Forente stater, 55102
- United Hospital
-
Sandstone, Minnesota, Forente stater, 55072
- Essentia Health Sandstone
-
Shakopee, Minnesota, Forente stater, 55379
- Saint Francis Regional Medical Center
-
Stillwater, Minnesota, Forente stater, 55082
- Lakeview Hospital
-
Virginia, Minnesota, Forente stater, 55792
- Essentia Health Virginia Clinic
-
Waconia, Minnesota, Forente stater, 55387
- Ridgeview Medical Center
-
Willmar, Minnesota, Forente stater, 56201
- Rice Memorial Hospital
-
Woodbury, Minnesota, Forente stater, 55125
- Minnesota Oncology Hematology PA-Woodbury
-
Wyoming, Minnesota, Forente stater, 55092
- Fairview Lakes Medical Center
-
-
Missouri
-
Ballwin, Missouri, Forente stater, 63011
- Mercy Oncology and Hematology - Clayton-Clarkson
-
Bolivar, Missouri, Forente stater, 65613
- Central Care Cancer Center - Bolivar
-
Branson, Missouri, Forente stater, 65616
- Cox Cancer Center Branson
-
Cape Girardeau, Missouri, Forente stater, 63703
- Saint Francis Medical Center
-
Cape Girardeau, Missouri, Forente stater, 63703
- Mercy Cancer Center - Cape Girardeau
-
City of Saint Peters, Missouri, Forente stater, 63376
- Siteman Cancer Center at Saint Peters Hospital
-
Columbia, Missouri, Forente stater, 65212
- MU Health - University Hospital/Ellis Fischel Cancer Center
-
Creve Coeur, Missouri, Forente stater, 63141
- Siteman Cancer Center at West County Hospital
-
Farmington, Missouri, Forente stater, 63640
- Parkland Health Center - Farmington
-
Jefferson City, Missouri, Forente stater, 65109
- MU Health Care Goldschmidt Cancer Center
-
Joplin, Missouri, Forente stater, 64804
- Freeman Health System
-
Joplin, Missouri, Forente stater, 64804
- Mercy Hospital Joplin
-
Kansas City, Missouri, Forente stater, 64111
- Saint Luke's Hospital of Kansas City
-
Kansas City, Missouri, Forente stater, 64108
- University Health Truman Medical Center
-
Lee's Summit, Missouri, Forente stater, 64086
- Saint Luke's East - Lee's Summit
-
Rolla, Missouri, Forente stater, 65401
- Mercy Clinic-Rolla-Cancer and Hematology
-
Rolla, Missouri, Forente stater, 65401
- Phelps Health Delbert Day Cancer Institute
-
Saint Joseph, Missouri, Forente stater, 64506
- Heartland Regional Medical Center
-
Sainte Genevieve, Missouri, Forente stater, 63670
- Sainte Genevieve County Memorial Hospital
-
Springfield, Missouri, Forente stater, 65807
- CoxHealth South Hospital
-
Springfield, Missouri, Forente stater, 65804
- Mercy Hospital Springfield
-
St Louis, Missouri, Forente stater, 63110
- Washington University School of Medicine
-
St Louis, Missouri, Forente stater, 63129
- Siteman Cancer Center-South County
-
St Louis, Missouri, Forente stater, 63136
- Siteman Cancer Center at Christian Hospital
-
St Louis, Missouri, Forente stater, 63131
- Missouri Baptist Medical Center
-
St Louis, Missouri, Forente stater, 63109
- Mercy Infusion Center - Chippewa
-
St Louis, Missouri, Forente stater, 63141
- Mercy Hospital Saint Louis
-
St Louis, Missouri, Forente stater, 63128
- Mercy Hospital South
-
Sullivan, Missouri, Forente stater, 63080
- Missouri Baptist Sullivan Hospital
-
Washington, Missouri, Forente stater, 63090
- Mercy Hospital Washington
-
-
Montana
-
Anaconda, Montana, Forente stater, 59711
- Community Hospital of Anaconda
-
Billings, Montana, Forente stater, 59101
- Billings Clinic Cancer Center
-
Billings, Montana, Forente stater, 59101
- Saint Vincent Healthcare
-
Billings, Montana, Forente stater, 59102
- Saint Vincent Frontier Cancer Center
-
Bozeman, Montana, Forente stater, 59715
- Bozeman Health Deaconess Hospital
-
Great Falls, Montana, Forente stater, 59405
- Great Falls Clinic
-
Great Falls, Montana, Forente stater, 59405
- Benefis Sletten Cancer Institute
-
Kalispell, Montana, Forente stater, 59901
- Logan Health Medical Center
-
Missoula, Montana, Forente stater, 59802
- Saint Patrick Hospital - Community Hospital
-
Missoula, Montana, Forente stater, 59804
- Community Medical Center
-
-
Nebraska
-
Bellevue, Nebraska, Forente stater, 68123
- Nebraska Medicine-Bellevue
-
Grand Island, Nebraska, Forente stater, 68803
- Nebraska Cancer Specialists/Oncology Hematology West PC
-
Kearney, Nebraska, Forente stater, 68847
- CHI Health Good Samaritan
-
Lincoln, Nebraska, Forente stater, 68510
- Saint Elizabeth Regional Medical Center
-
Omaha, Nebraska, Forente stater, 68114
- Nebraska Methodist Hospital
-
Omaha, Nebraska, Forente stater, 68198
- University of Nebraska Medical Center
-
Omaha, Nebraska, Forente stater, 68124
- Alegent Health Bergan Mercy Medical Center
-
Omaha, Nebraska, Forente stater, 68118
- Nebraska Medicine-Village Pointe
-
Omaha, Nebraska, Forente stater, 68122
- Alegent Health Immanuel Medical Center
-
Omaha, Nebraska, Forente stater, 68130
- Alegent Health Lakeside Hospital
-
Omaha, Nebraska, Forente stater, 68114
- Oncology Associates PC
-
Omaha, Nebraska, Forente stater, 68114
- Nebraska Cancer Specialists/Oncology Hematology West PC - MECC
-
Papillion, Nebraska, Forente stater, 68046
- Midlands Community Hospital
-
-
Nevada
-
Carson City, Nevada, Forente stater, 89703
- Carson Tahoe Regional Medical Center
-
Henderson, Nevada, Forente stater, 89052
- Comprehensive Cancer Centers of Nevada - Henderson
-
Henderson, Nevada, Forente stater, 89052
- Cancer and Blood Specialists-Henderson
-
Henderson, Nevada, Forente stater, 89052
- Las Vegas Cancer Center-Henderson
-
Henderson, Nevada, Forente stater, 89074
- Comprehensive Cancer Centers of Nevada-Southeast Henderson
-
Henderson, Nevada, Forente stater, 89052
- Comprehensive Cancer Centers of Nevada-Horizon Ridge
-
Henderson, Nevada, Forente stater, 89074
- Las Vegas Urology - Green Valley
-
Henderson, Nevada, Forente stater, 89074
- Las Vegas Urology - Pebble
-
Henderson, Nevada, Forente stater, 89074
- Urology Specialists of Nevada - Green Valley
-
Henderson, Nevada, Forente stater, 89074
- Oncology Las Vegas - Henderson
-
Las Vegas, Nevada, Forente stater, 89144
- Summerlin Hospital Medical Center
-
Las Vegas, Nevada, Forente stater, 89109
- Sunrise Hospital and Medical Center
-
Las Vegas, Nevada, Forente stater, 89102
- OptumCare Cancer Care at Charleston
-
Las Vegas, Nevada, Forente stater, 89106
- Radiation Oncology Centers of Nevada Central
-
Las Vegas, Nevada, Forente stater, 89119
- Radiation Oncology Centers of Nevada Southeast
-
Las Vegas, Nevada, Forente stater, 89128
- Comprehensive Cancer Centers of Nevada - Northwest
-
Las Vegas, Nevada, Forente stater, 89128
- OptumCare Cancer Care at MountainView
-
Las Vegas, Nevada, Forente stater, 89135
- Alliance for Childhood Diseases/Cure 4 the Kids Foundation
-
Las Vegas, Nevada, Forente stater, 89144
- Comprehensive Cancer Centers of Nevada - Town Center
-
Las Vegas, Nevada, Forente stater, 89144
- Comprehensive Cancer Centers of Nevada-Summerlin
-
Las Vegas, Nevada, Forente stater, 89148
- Comprehensive Cancer Centers of Nevada
-
Las Vegas, Nevada, Forente stater, 89169
- Comprehensive Cancer Centers of Nevada - Central Valley
-
Las Vegas, Nevada, Forente stater, 89102
- University Medical Center of Southern Nevada
-
Las Vegas, Nevada, Forente stater, 89106
- Cancer and Blood Specialists-Shadow
-
Las Vegas, Nevada, Forente stater, 89109
- HealthCare Partners Medical Group Oncology/Hematology-Maryland Parkway
-
Las Vegas, Nevada, Forente stater, 89113
- HealthCare Partners Medical Group Oncology/Hematology-San Martin
-
Las Vegas, Nevada, Forente stater, 89128
- Cancer and Blood Specialists-Tenaya
-
Las Vegas, Nevada, Forente stater, 89128
- HealthCare Partners Medical Group Oncology/Hematology-Tenaya
-
Las Vegas, Nevada, Forente stater, 89148-2405
- Las Vegas Cancer Center-Medical Center
-
Las Vegas, Nevada, Forente stater, 89149
- HealthCare Partners Medical Group Oncology/Hematology-Centennial Hills
-
Las Vegas, Nevada, Forente stater, 89128
- Ann M Wierman MD LTD
-
Las Vegas, Nevada, Forente stater, 89074
- Las Vegas Urology - Pecos
-
Las Vegas, Nevada, Forente stater, 89102
- Desert West Surgery
-
Las Vegas, Nevada, Forente stater, 89103
- Hope Cancer Care of Nevada
-
Las Vegas, Nevada, Forente stater, 89106
- Urology Specialists of Nevada - Central
-
Las Vegas, Nevada, Forente stater, 89113
- Las Vegas Prostate Cancer Center
-
Las Vegas, Nevada, Forente stater, 89113
- Las Vegas Urology - Sunset
-
Las Vegas, Nevada, Forente stater, 89128
- Las Vegas Urology - Cathedral Rock
-
Las Vegas, Nevada, Forente stater, 89128
- Las Vegas Urology - Smoke Ranch
-
Las Vegas, Nevada, Forente stater, 89128
- Urology Specialists of Nevada - Northwest
-
Las Vegas, Nevada, Forente stater, 89169
- University Cancer Center
-
Las Vegas, Nevada, Forente stater, 89113
- Urology Specialists of Nevada - Southwest
-
Las Vegas, Nevada, Forente stater, 89128
- Oncology Las Vegas - Tenaya
-
Las Vegas, Nevada, Forente stater, 89183
- OptumCare Cancer Care at Fort Apache
-
Pahrump, Nevada, Forente stater, 89048
- Hope Cancer Care of Nevada-Pahrump
-
Reno, Nevada, Forente stater, 89502
- Renown Regional Medical Center
-
Reno, Nevada, Forente stater, 89503
- Saint Mary's Regional Medical Center
-
Reno, Nevada, Forente stater, 89509
- Radiation Oncology Associates
-
-
New Hampshire
-
Concord, New Hampshire, Forente stater, 03301
- New Hampshire Oncology Hematology PA-Concord
-
Manchester, New Hampshire, Forente stater, 03103
- Solinsky Center for Cancer Care
-
Manchester, New Hampshire, Forente stater, 03103
- Elliot Hospital
-
-
New Jersey
-
Moorestown, New Jersey, Forente stater, 08057
- Virtua Samson Cancer Center
-
Mount Holly, New Jersey, Forente stater, 08060
- Virtua Memorial
-
Voorhees Township, New Jersey, Forente stater, 08043
- Virtua Voorhees
-
-
New Mexico
-
Albuquerque, New Mexico, Forente stater, 87106
- University of New Mexico Cancer Center
-
-
New York
-
Glens Falls, New York, Forente stater, 12801
- Glens Falls Hospital
-
The Bronx, New York, Forente stater, 10461
- Montefiore Medical Center-Einstein Campus
-
The Bronx, New York, Forente stater, 10467
- Montefiore Medical Center - Moses Campus
-
The Bronx, New York, Forente stater, 10461
- Montefiore Medical Center-Weiler Hospital
-
-
North Carolina
-
Kenansville, North Carolina, Forente stater, 28349
- ECU Health Oncology Kenansville
-
Kinston, North Carolina, Forente stater, 28501
- ECU Health Oncology Kinston
-
Pinehurst, North Carolina, Forente stater, 28374
- FirstHealth of the Carolinas-Moore Regional Hospital
-
Richlands, North Carolina, Forente stater, 28574
- ECU Health Oncology Richlands
-
Washington, North Carolina, Forente stater, 27889
- Marion L Shepard Cancer Center - ECU Health Beaufort Hospital
-
-
North Dakota
-
Fargo, North Dakota, Forente stater, 58103
- Essentia Health Cancer Center-South University Clinic
-
Jamestown, North Dakota, Forente stater, 58401
- Essentia Health - Jamestown Clinic
-
-
Ohio
-
Alliance, Ohio, Forente stater, 44601
- Aultman Alliance Community Hospital
-
Beavercreek, Ohio, Forente stater, 45431
- Indu and Raj Soin Medical Center
-
Boardman, Ohio, Forente stater, 44512
- Saint Elizabeth Boardman Hospital
-
Canton, Ohio, Forente stater, 44708
- Cleveland Clinic Mercy Hospital
-
Canton, Ohio, Forente stater, 44710
- Aultman Health Foundation
-
Centerville, Ohio, Forente stater, 45459
- Miami Valley Hospital South
-
Centerville, Ohio, Forente stater, 45459
- Dayton Physicians LLC-Miami Valley South
-
Cincinnati, Ohio, Forente stater, 45220
- Good Samaritan Hospital - Cincinnati
-
Cincinnati, Ohio, Forente stater, 45242
- Bethesda North Hospital
-
Cincinnati, Ohio, Forente stater, 45236
- Oncology Hematology Care Inc-Kenwood
-
Cincinnati, Ohio, Forente stater, 45247
- TriHealth Cancer Institute-Westside
-
Cincinnati, Ohio, Forente stater, 45255
- TriHealth Cancer Institute-Anderson
-
Cleveland, Ohio, Forente stater, 44195
- Cleveland Clinic Foundation
-
Cleveland, Ohio, Forente stater, 44111
- Cleveland Clinic Cancer Center/Fairview Hospital
-
Dayton, Ohio, Forente stater, 45409
- Miami Valley Hospital
-
Dayton, Ohio, Forente stater, 45415
- Miami Valley Hospital North
-
Dayton, Ohio, Forente stater, 45415
- Dayton Physician LLC - Englewood
-
Dayton, Ohio, Forente stater, 45409
- Premier Blood and Cancer Center
-
Findlay, Ohio, Forente stater, 45840
- Blanchard Valley Hospital
-
Findlay, Ohio, Forente stater, 45840
- Armes Family Cancer Center
-
Findlay, Ohio, Forente stater, 45840
- Orion Cancer Care
-
Franklin, Ohio, Forente stater, 45005-1066
- Atrium Medical Center-Middletown Regional Hospital
-
Franklin, Ohio, Forente stater, 45005
- Dayton Physicians LLC-Atrium
-
Greenville, Ohio, Forente stater, 45331
- Wayne Hospital
-
Greenville, Ohio, Forente stater, 45331
- Dayton Physicians LLC-Wayne
-
Greenville, Ohio, Forente stater, 45331
- Miami Valley Cancer Care and Infusion
-
Kettering, Ohio, Forente stater, 45429
- Kettering Medical Center
-
Kettering, Ohio, Forente stater, 45409
- Greater Dayton Cancer Center
-
Kettering, Ohio, Forente stater, 45420
- First Dayton Cancer Care
-
Mansfield, Ohio, Forente stater, 44906
- Cleveland Clinic Cancer Center Mansfield
-
Maumee, Ohio, Forente stater, 43537
- Toledo Clinic Cancer Centers-Maumee
-
Mayfield Heights, Ohio, Forente stater, 44124
- Hillcrest Hospital Cancer Center
-
Perrysburg, Ohio, Forente stater, 43551
- Mercy Health - Perrysburg Hospital
-
Sandusky, Ohio, Forente stater, 44870
- North Coast Cancer Care
-
Springfield, Ohio, Forente stater, 45504
- Springfield Regional Cancer Center
-
Springfield, Ohio, Forente stater, 45504
- Springfield Regional Medical Center
-
Strongsville, Ohio, Forente stater, 44136
- Cleveland Clinic Cancer Center Strongsville
-
Toledo, Ohio, Forente stater, 43623
- Mercy Health - Saint Anne Hospital
-
Toledo, Ohio, Forente stater, 43623
- Toledo Clinic Cancer Centers-Toledo
-
Troy, Ohio, Forente stater, 45373
- Upper Valley Medical Center
-
Troy, Ohio, Forente stater, 45373
- Dayton Physicians LLC - Troy
-
Warren, Ohio, Forente stater, 44484
- Saint Joseph Warren Hospital
-
Warrensville Heights, Ohio, Forente stater, 44122
- South Pointe Hospital
-
Wooster, Ohio, Forente stater, 44691
- Cleveland Clinic Wooster Family Health and Surgery Center
-
Wright-Patterson Air Force Base, Ohio, Forente stater, 45433
- Wright-Patterson Medical Center
-
Youngstown, Ohio, Forente stater, 44501
- Saint Elizabeth Youngstown Hospital
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Forente stater, 73120
- Mercy Hospital Oklahoma City
-
-
Oregon
-
Baker City, Oregon, Forente stater, 97814
- Saint Alphonsus Cancer Care Center-Baker City
-
Bend, Oregon, Forente stater, 97701
- Saint Charles Health System
-
Clackamas, Oregon, Forente stater, 97015
- Clackamas Radiation Oncology Center
-
Clackamas, Oregon, Forente stater, 97015
- Providence Cancer Institute Clackamas Clinic
-
Coos Bay, Oregon, Forente stater, 97420
- Bay Area Hospital
-
Newberg, Oregon, Forente stater, 97132
- Providence Newberg Medical Center
-
Ontario, Oregon, Forente stater, 97914
- Saint Alphonsus Cancer Care Center-Ontario
-
Oregon City, Oregon, Forente stater, 97045
- Providence Willamette Falls Medical Center
-
Portland, Oregon, Forente stater, 97239
- Oregon Health and Science University
-
Portland, Oregon, Forente stater, 97213
- Providence Portland Medical Center
-
Portland, Oregon, Forente stater, 97225
- Providence Saint Vincent Medical Center
-
Redmond, Oregon, Forente stater, 97756
- Saint Charles Health System-Redmond
-
-
Pennsylvania
-
Allentown, Pennsylvania, Forente stater, 18103
- Lehigh Valley Hospital-Cedar Crest
-
Allentown, Pennsylvania, Forente stater, 18104
- Saint Luke's Cancer Center - Allentown
-
Bethlehem, Pennsylvania, Forente stater, 18017
- Lehigh Valley Hospital - Muhlenberg
-
Bethlehem, Pennsylvania, Forente stater, 18015
- Saint Luke's University Hospital-Bethlehem Campus
-
Bryn Mawr, Pennsylvania, Forente stater, 19010
- Bryn Mawr Hospital
-
Chambersburg, Pennsylvania, Forente stater, 17201
- Chambersburg Hospital
-
Chambersburg, Pennsylvania, Forente stater, 17201
- WellSpan Medical Oncology and Hematology
-
Collegeville, Pennsylvania, Forente stater, 19426
- Main Line Health Center-Collegeville
-
East Stroudsburg, Pennsylvania, Forente stater, 18301
- Pocono Medical Center
-
Easton, Pennsylvania, Forente stater, 18045
- Saint Luke's Hospital-Anderson Campus
-
Ephrata, Pennsylvania, Forente stater, 17522
- Ephrata Cancer Center
-
Exton, Pennsylvania, Forente stater, 19341
- Main Line Health Center-Exton
-
Gettysburg, Pennsylvania, Forente stater, 17325
- Adams Cancer Center
-
Hanover, Pennsylvania, Forente stater, 17331
- WellSpan Medical Oncology and Hematology
-
Hazleton, Pennsylvania, Forente stater, 18201
- Lehigh Valley Hospital-Hazleton
-
Lebanon, Pennsylvania, Forente stater, 17042
- Sechler Family Cancer Center
-
Media, Pennsylvania, Forente stater, 19063
- Riddle Memorial Hospital
-
Newtown Square, Pennsylvania, Forente stater, 19073
- Bryn Mawr Health Center
-
Paoli, Pennsylvania, Forente stater, 19301
- Paoli Memorial Hospital
-
Philadelphia, Pennsylvania, Forente stater, 19104
- University of Pennsylvania/Abramson Cancer Center
-
Philadelphia, Pennsylvania, Forente stater, 19104
- Penn Presbyterian Medical Center
-
Pottstown, Pennsylvania, Forente stater, 19464
- Pottstown Hospital
-
Quakertown, Pennsylvania, Forente stater, 18951
- Saint Luke's Hospital-Quakertown Campus
-
Quakertown, Pennsylvania, Forente stater, 18951
- Saint Luke's Hospital - Upper Bucks Campus
-
Sayre, Pennsylvania, Forente stater, 18840
- Guthrie Medical Group PC-Robert Packer Hospital
-
Wynnewood, Pennsylvania, Forente stater, 19096
- Lankenau Medical Center
-
York, Pennsylvania, Forente stater, 17403
- WellSpan Health-York Cancer Center
-
York, Pennsylvania, Forente stater, 17403
- WellSpan Health-York Hospital
-
York, Pennsylvania, Forente stater, 17403
- Cancer Care Associates of York
-
-
South Carolina
-
Greenwood, South Carolina, Forente stater, 29646
- Self Regional Healthcare
-
-
Texas
-
Bryan, Texas, Forente stater, 77802
- Saint Joseph Regional Cancer Center
-
-
Virginia
-
Mechanicsville, Virginia, Forente stater, 23116
- Bon Secours Memorial Regional Medical Center
-
Midlothian, Virginia, Forente stater, 23114
- Bon Secours Saint Francis Medical Center
-
Midlothian, Virginia, Forente stater, 23113
- Bon Secours Westchester Emergency Center
-
Norfolk, Virginia, Forente stater, 23505
- Bon Secours DePaul Medical Center
-
Portsmouth, Virginia, Forente stater, 23707
- Bon Secours Maryview Medical Center
-
Richmond, Virginia, Forente stater, 23235
- VCU Massey Cancer Center at Stony Point
-
Richmond, Virginia, Forente stater, 23226
- Bon Secours Saint Mary's Hospital
-
Richmond, Virginia, Forente stater, 23230
- Bon Secours Cancer Institute at Reynolds Crossing
-
Richmond, Virginia, Forente stater, 23223
- Bon Secours Richmond Community Hospital
-
Richmond, Virginia, Forente stater, 23298
- VCU Massey Comprehensive Cancer Center
-
Suffolk, Virginia, Forente stater, 23435
- Bon Secours Health Center at Harbour View
-
-
Washington
-
Aberdeen, Washington, Forente stater, 98520
- Providence Regional Cancer System-Aberdeen
-
Bellevue, Washington, Forente stater, 98004
- Overlake Medical Center
-
Bellingham, Washington, Forente stater, 98225
- PeaceHealth Saint Joseph Medical Center
-
Burien, Washington, Forente stater, 98166
- Saint Anne Hospital
-
Centralia, Washington, Forente stater, 98531
- Providence Regional Cancer System-Centralia
-
Edmonds, Washington, Forente stater, 98026
- Swedish Cancer Institute-Edmonds
-
Enumclaw, Washington, Forente stater, 98022
- Saint Elizabeth Hospital
-
Everett, Washington, Forente stater, 98201
- Providence Regional Cancer Partnership
-
Federal Way, Washington, Forente stater, 98003
- Saint Francis Hospital
-
Issaquah, Washington, Forente stater, 98029
- Swedish Cancer Institute-Issaquah
-
Kennewick, Washington, Forente stater, 99336
- Kadlec Clinic Hematology and Oncology
-
Lacey, Washington, Forente stater, 98503
- Providence Regional Cancer System-Lacey
-
Lakewood, Washington, Forente stater, 98499
- Saint Clare Hospital
-
Longview, Washington, Forente stater, 98632
- PeaceHealth Saint John Medical Center
-
Port Townsend, Washington, Forente stater, 98368
- Jefferson Healthcare
-
Poulsbo, Washington, Forente stater, 98370
- Harrison HealthPartners Hematology and Oncology-Poulsbo
-
Renton, Washington, Forente stater, 98055
- Valley Medical Center
-
Seattle, Washington, Forente stater, 98107
- Swedish Medical Center-Ballard Campus
-
Seattle, Washington, Forente stater, 98122
- Swedish Medical Center-First Hill
-
Seattle, Washington, Forente stater, 98104
- Pacific Gynecology Specialists
-
Seattle, Washington, Forente stater, 98122-5711
- Swedish Medical Center-Cherry Hill
-
Sedro-Woolley, Washington, Forente stater, 98284
- PeaceHealth United General Medical Center
-
Shelton, Washington, Forente stater, 98584
- Providence Regional Cancer System-Shelton
-
Silverdale, Washington, Forente stater, 98383
- Saint Joseph Medical Center Hematology and Oncology - Silverdale
-
Tacoma, Washington, Forente stater, 98405
- Northwest Medical Specialties PLLC
-
Tacoma, Washington, Forente stater, 98405
- Franciscan Research Center-Northwest Medical Plaza
-
Vancouver, Washington, Forente stater, 98664
- PeaceHealth Southwest Medical Center
-
Walla Walla, Washington, Forente stater, 99362
- Providence Saint Mary Regional Cancer Center
-
Yakima, Washington, Forente stater, 98902
- North Star Lodge Cancer Center at Yakima Valley Memorial Hospital
-
Yelm, Washington, Forente stater, 98597
- Providence Regional Cancer System-Yelm
-
-
West Virginia
-
Huntington, West Virginia, Forente stater, 25701
- Edwards Comprehensive Cancer Center
-
-
Wisconsin
-
Appleton, Wisconsin, Forente stater, 54911
- ThedaCare Regional Cancer Center
-
Ashland, Wisconsin, Forente stater, 54806
- Duluth Clinic Ashland
-
Ashland, Wisconsin, Forente stater, 54806
- Northwest Wisconsin Cancer Center
-
Berlin, Wisconsin, Forente stater, 54923
- ThedaCare Cancer Care - Berlin
-
Burlington, Wisconsin, Forente stater, 53105
- Aurora Cancer Care-Southern Lakes VLCC
-
Chippewa Falls, Wisconsin, Forente stater, 54729
- Marshfield Clinic-Chippewa Center
-
Cudahy, Wisconsin, Forente stater, 53110
- Aurora Saint Luke's South Shore
-
Eau Claire, Wisconsin, Forente stater, 54701
- Marshfield Medical Center-EC Cancer Center
-
Germantown, Wisconsin, Forente stater, 53022
- Aurora Health Care Germantown Health Center
-
Grafton, Wisconsin, Forente stater, 53024
- Aurora Cancer Care-Grafton
-
Green Bay, Wisconsin, Forente stater, 54311
- Aurora BayCare Medical Center
-
Hayward, Wisconsin, Forente stater, 54843
- Essentia Health-Hayward Clinic
-
Kenosha, Wisconsin, Forente stater, 53142
- Aurora Cancer Care-Kenosha South
-
La Crosse, Wisconsin, Forente stater, 54601
- Gundersen Lutheran Medical Center
-
Ladysmith, Wisconsin, Forente stater, 54848
- Marshfield Medical Center - Ladysmith
-
Marinette, Wisconsin, Forente stater, 54143
- Aurora Bay Area Medical Group-Marinette
-
Marshfield, Wisconsin, Forente stater, 54449
- Marshfield Medical Center-Marshfield
-
Milwaukee, Wisconsin, Forente stater, 53209
- Aurora Cancer Care-Milwaukee
-
Milwaukee, Wisconsin, Forente stater, 53215
- Aurora Saint Luke's Medical Center
-
Milwaukee, Wisconsin, Forente stater, 53233
- Aurora Sinai Medical Center
-
Minocqua, Wisconsin, Forente stater, 54548
- Marshfield Medical Center - Minocqua
-
Mukwonago, Wisconsin, Forente stater, 53149
- ProHealth D N Greenwald Center
-
New Richmond, Wisconsin, Forente stater, 54017
- Cancer Center of Western Wisconsin
-
Oconomowoc, Wisconsin, Forente stater, 53066
- ProHealth Oconomowoc Memorial Hospital
-
Oshkosh, Wisconsin, Forente stater, 54904
- Vince Lombardi Cancer Clinic - Oshkosh
-
Racine, Wisconsin, Forente stater, 53406
- Aurora Cancer Care-Racine
-
Rice Lake, Wisconsin, Forente stater, 54868
- Marshfield Medical Center-Rice Lake
-
Sheboygan, Wisconsin, Forente stater, 53081
- Vince Lombardi Cancer Clinic-Sheboygan
-
Spooner, Wisconsin, Forente stater, 54801
- Essentia Health-Spooner Clinic
-
Stevens Point, Wisconsin, Forente stater, 54482
- Marshfield Medical Center-River Region at Stevens Point
-
Summit, Wisconsin, Forente stater, 53066
- Aurora Medical Center in Summit
-
Superior, Wisconsin, Forente stater, 54880
- Essentia Health Saint Mary's Hospital - Superior
-
Two Rivers, Wisconsin, Forente stater, 54241
- Vince Lombardi Cancer Clinic-Two Rivers
-
Waukesha, Wisconsin, Forente stater, 53188
- UW Cancer Center at ProHealth Care
-
Waukesha, Wisconsin, Forente stater, 53188
- ProHealth Waukesha Memorial Hospital
-
Wausau, Wisconsin, Forente stater, 54401
- Marshfield Clinic-Wausau Center
-
Wauwatosa, Wisconsin, Forente stater, 53226
- Aurora Cancer Care-Milwaukee West
-
Weston, Wisconsin, Forente stater, 54476
- Marshfield Medical Center - Weston
-
Wisconsin Rapids, Wisconsin, Forente stater, 54494
- Marshfield Clinic - Wisconsin Rapids Center
-
-
Wyoming
-
Cheyenne, Wyoming, Forente stater, 82001
- Cheyenne Regional Medical Center-West
-
Cody, Wyoming, Forente stater, 82414
- Billings Clinic-Cody
-
Sheridan, Wyoming, Forente stater, 82801
- Welch Cancer Center
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
-
RANDOMIZATION (STEP 1): Patient must be >= 18 years of age
-
RANDOMIZATION (STEP 1): Patient must have pathologically confirmed non-squamous non-small cell lung carcinoma (NSCLC). Patients with NSCLC not otherwise specified (NOS) are eligible. Mixed tumors will be categorized by predominant cell type. If small cell elements are present, the patient is ineligible
-
RANDOMIZATION (STEP 1): Patient must have metastatic stage IVA or IVB disease (includes M1a, M1b, and M1c), according to the 8th edition of the lung cancer TNM classification system. Recurrent metastatic NSCLC ineligible for curative therapy (in the treating investigator's opinion) is also allowed
-
RANDOMIZATION (STEP 1): Patient's tumor must be known negative for EGFR tyrosine kinase inhibitor (TKI) sensitizing mutations (for example at a minimum, negative for EGFR Exon 19 deletions, EGFR exon 20 insertions, and Exon 21 L858R, L861Q mutations ) AND negative for ALK gene rearrangements (by fluorescence in situ hybridization [FISH], next generation sequencing [NGS], or immunohistochemistry [IHC]) by routine Clinical Laboratory Improvement Amendments (CLIA)- or Food and Drug Administration (FDA)-certified clinical testing methods. CLIA or FDA approved circulating tumor deoxyribonucleic acid (DNA) testing is acceptable as an alternative to tissue testing
-
RANDOMIZATION (STEP 1): Patient must have radiographic and/or clinical progression (per local investigator assessment) following one, but only one, line of platinum-based chemotherapy AND one, but only one, line of prior checkpoint inhibitor (anti-PD-1 or PD-L1) immunotherapy, either concurrently or sequentially in either order. A minimum of two doses of prior immunotherapy is required. Only one prior line of therapy is allowed if patients received chemotherapy and immunotherapy together (patients may not receive subsequent single agent chemotherapy), and greater than two prior lines of therapy are not allowed.
- NOTE: Lines of therapy are defined by clinical or radiographic progression. For patients with recurrent metastatic NSCLC following treatment for stage 1-3 NSCLC, platinum-based chemotherapy received within 12 months of recurrence and/or immunotherapy received within 6 months of recurrence will meet the requirement for prior chemotherapy and/or immunotherapy but subsequent receipt of more immunotherapy and/or platinum-based chemotherapy is also allowed.
- NOTE: Prior anti-VEGF antibody therapy (ie bevacizumab) is allowed. Prior ipilimumab, or investigational agents not excluded below, in combination with the required prior therapies above are allowed.
- NOTE: Prior receipt of one or two lines of targeted therapy for ROS1, RET, MET, BRAF, ERBB2/HER2, or KRAS G12C positive NSCLC is allowed and will not count toward the line of therapy limit. However, progression is still required after chemotherapy and immunotherapy as above. Patients with ROS1, RET, MET positive NSCLC are strongly encouraged to get appropriate targeted therapy (such as crizotinib, entrectinib, lorlatinib, selpercatinib, pralsetinib, capmatinib, tepotinib, or another investigational, off-label, or approved agent directed against ROS1, RET, or MET positive NSCLC) prior to participation and will be stratified.
- NOTE: No prior predominantly VEGFR directed TKI therapy (such as cabozantinib, lenvatinib, or sitravantinib) is allowed, except for the agents named above.
-
RANDOMIZATION (STEP 1): The investigator must document the intended chemotherapy regimen should their patient be randomized to Arm C (docetaxel and ramucirumab, OR single agent chemotherapy - docetaxel, gemcitabine, paclitaxel, nab-paclitaxel). The patient must not have received the selected chemotherapy agent previously for metastatic disease
-
RANDOMIZATION (STEP 1): Any prior chemotherapy (based on administration schedule) must have been completed in greater than or equal to the following times prior to randomization:
- FDA approved targeted oral therapy must be completed >= 1 week prior
- Chemotherapy and/or immunotherapy must be completed >= 2 weeks prior
- Prior investigational agents must be completed >= 4 weeks prior.
-
RANDOMIZATION (STEP 1): Prior radiation therapy is allowed with a 2 week washout prior to randomization. Patient must not receive any systemic treatment with radionuclides within 6 weeks prior to randomization. Patient must have no clinically relevant ongoing complication from prior radiation therapy
-
RANDOMIZATION (STEP 1): Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen (in the opinion of the treating physician) are eligible for this trial
-
RANDOMIZATION (STEP 1): Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents (such as anthracycline or HER2-directed antibody therapy, but not prior checkpoint inhibitor therapy), must have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients must be class 2B or better
-
RANDOMIZATION (STEP 1): Patient must have Eastern Cooperative Oncology Group (ECOG) performance status 0-1
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Patient must have met the eligibility criteria outlined above
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Patient must have measurable disease as defined by RECIST v1.1. Measurements must be obtained within 4 weeks prior to randomization/registration
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Patient must have recovered to equal to or less than grade 1 toxicities related to prior treatment, unless toxicities are clinically non significant and/or stable on supportive therapy (as determined by the treating physician)
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Absolute neutrophil count >= 1,500/mcL (obtained within 2 weeks prior to randomization)
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Platelets >= 100,000/mcL (obtained within 2 weeks prior to randomization)
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Hemoglobin >= 9 g/dL (obtained within 2 weeks prior to randomization)
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) (for patients with Gilbert's disease total bilirubin must be =< 3 x ULN) (obtained within 2 weeks prior to randomization)
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT)(serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x ULN (obtained within 2 weeks prior to randomization)
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Creatinine =< 1.5 x ULN OR calculated (Cockcroft-Gault formula) or measured creatinine clearance >= 50 mL/min/1.73m^2 (normalized to body surface area [BSA]) for patients with creatinine levels greater than 1.5 times the institutional normal creatinine =< 1.5 X ULN or creatinine clearance >= 50ml/min/1.73m^2 (obtained within 2 weeks prior to randomization)
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Patients must not be pregnant or breast-feeding due to the unknown effects of cabozantinib and nivolumab on human development and for the potential risk for adverse events in nursing infants with the treatment regimens being used.
- All patients of childbearing potential must have a blood test or urine study within 14 days prior to randomization/registration to rule out pregnancy.
- A patient of childbearing potential is anyone, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months).
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Patients must not expect to conceive or father children by using accepted and effective method(s) of contraception or by abstaining from sexual intercourse for the duration of their participation in the study and for 6 months after completion of treatment on the study
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Patients must not have clinically significant gastrointestinal bleeding within 6 months prior to randomization
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Patients must not have pulmonary hemorrhage or hemoptysis of >= 0.5 teaspoon (2.5 mL) of red blood within 3 months prior to randomization
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Patients must not have active drug induced pneumonitis within 3 months prior to randomization. Prior immune mediated pneumonitis of grade 3 or 4 are not eligible regardless of time window
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Patients must not have current radiographic evidence of tumor invading major blood vessel, evidence of tumor cavitation > 1 cm, evidence of tumor invading the gastrointestinal (GI) tract (esophagus, stomach, small or large bowel, rectum or anus), or evidence of endotracheal or mainstem endobronchial tumor
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Patients must not have peptic ulcer disease, known malabsorption syndrome, bowel obstruction or gastric outlet obstruction within 3 months prior to randomization
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Patients must not have abdominal fistula, GI perforation, or intra-abdominal abscess within 6 months prior to randomization
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Patients must not have grade 3 or greater infection, or infection requiring intravenous systemic treatment within 14 days prior to randomization. Patients must be off antibiotics at the time of randomization
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Patients must not have serious non-healing wound/ulcer/bone fracture within 28 days prior to randomization
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Patients must not have history of organ transplant
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Patients must not have concurrent symptomatic untreated hypothyroidism
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Patients must not have history of major surgery within 3 months prior to randomization, minor surgery within 28 days prior to randomization, other minor procedures within 7 days prior to randomization, or clinically relevant ongoing complications from prior procedures
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Patients must not have concurrent uncontrolled hypertension defined as sustained blood pressure (BP) > 160 mm Hg systolic, or > 100 mm Hg diastolic despite optimal antihypertensive treatment
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Patients must not have unstable angina pectoris, clinically-significant cardiac arrhythmias, stroke (including transient ischemic attack [TIA]), or myocardial infarction within 6 months prior to randomization
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Patients must not have a diagnosis of deep vein thrombosis/pulmonary embolism (DVT/PE) within 6 months of randomization unless stable, asymptomatic, and treated with low-molecular-weight heparin (LMWH) or a permitted oral anticoagulant for at least 7 days before randomization
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Patient must not be receiving anticoagulants (i.e., warfarin, aspirin, clopidogrel) except:
- Prophylactic use of low-dose aspirin (100 mg po daily or less) and/or low dose molecular weight heparin (LMWH) is permitted.
- Therapeutic doses of low dose molecular weight heparin (LMWH) or specified direct factor Xa inhibitors rivaroxaban, edoxaban, or apixaban are allowed in patients without untreated brain metastases who are on a stable dose 7 days prior to study randomization, and without clinically significant hemorrhagic complications from the anticoagulation regimen or the tumor
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Patient must not receive strong CYP3A4 inducers (e.g., dexamethasone (> 1 mg daily dosing), phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital, and St. John's Wort) within 7 days prior to randomization
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Patient must have corrected QT interval calculated by the Fridericia formula (QTcF) =< 500 msec within 28 days prior to Step 1 randomization
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Patient must be able to swallow tablets
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Patient must not be on continuous systemic treatment with corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 7 days prior to randomization, with the following exceptions:
- Inhaled or topical steroids and adrenal replacement doses =< 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.
- Patients are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption).
- Physiologic replacement doses of systemic corticosteroids are permitted, if < 10 mg/day prednisone equivalents. A brief course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction caused by contact allergen) is permitted
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Patients with brain metastases are eligible as follows:
- Previously treated brain metastases must have been treated with radiation > 2 weeks prior to randomization or surgery > 3 months prior to randomization OR
- Untreated (active) brain metastases are allowed if they are clinically asymptomatic, < 1 cm, non-hemorrhagic, the patient is not on systemic anticoagulation, and the investigator believes that central nervous system (CNS) specific treatment is unlikely to be required during the first 3 months of study treatment.
- NOTE: Symptomatic leptomeningeal disease is NOT allowed
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Patient must not have known active autoimmune disease or known history of autoimmune disease for which recurrence may affect vital organ function or require immune suppressive treatment including systemic corticosteroids (e.g., immune-related neurologic disease, multiple sclerosis, autoimmune neuropathy, Guillain-Barre syndrome, etc.).
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Patients with known history of human immunodeficiency virus (HIV)-infection must be on effective anti-retroviral therapy with undetectable viral load within 6 months of randomization
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Patients with known history of chronic hepatitis B virus (HBV) infection must have undetectable HBV viral at time of randomization (suppressive therapy is allowed, if indicated)
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Patients with a known history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load at time of randomization
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Patient must not have had any prior allergic reaction or hypersensitivity to study drug components or related drugs (multitargeted small molecule tyrosine kinase inhibitors or checkpoint inhibitor monoclonal antibodies)
-
STEP 2 (CROSSOVER ARM Z): Patient must have met all eligibility requirements for Step 1 at time of registration to Step 1 to be eligible for Step 2
-
STEP 2 (CROSSOVER ARM Z): Patient must have radiographic progressive disease per RECIST criteria after >= 2 cycles of therapy on Arm C. The scan showing progression must be completed within 6 weeks prior to Step 2 registration
-
STEP 2 (CROSSOVER ARM Z): Patient must not have intervening anticancer treatment or major surgical procedure(s) between Step 1 and Step 2, except palliative radiation which was completed >= 1 week prior to registration to Step 2
-
STEP 2 (CROSSOVER ARM Z): Patient may not have central nervous system progression, but patients with stable CNS disease are allowed
-
STEP 2 (CROSSOVER ARM Z): Patient must have an ECOG performance status 0-2
-
STEP 2 (CROSSOVER ARM Z): Patient must have recovered to equal to or less than grade 1 toxicities related to prior treatment, unless the adverse event(s) are clinically non significant and/or stable on supportive therapy (as determined by the treating physician)
-
STEP 2 (CROSSOVER ARM Z): Absolute neutrophil count >= 1,500/mcL (obtained within 2 weeks prior to registration to Step 2)
-
STEP 2 (CROSSOVER ARM Z): Platelets >= 100,000/mcL (obtained within 2 weeks prior to registration to Step 2)
-
STEP 2 (CROSSOVER ARM Z): Hemoglobin >= 9 g/dL (obtained within 2 weeks prior to registration to Step 2)
-
STEP 2 (CROSSOVER ARM Z): Total bilirubin =< 1.5 x institutional ULN (for patients with Gilbert's disease total bilirubin must be =< 3 x ULN) (obtained within 2 weeks prior to registration to Step 2)
-
STEP 2 (CROSSOVER ARM Z): AST(SGOT) and ALT(SGPT) =< 2.5 x ULN (obtained within 2 weeks prior to registration to Step 2)
-
STEP 2 (CROSSOVER ARM Z): Creatinine =< 1.5 x ULN OR calculated (Cockcroft-Gault formula) or measured creatinine clearance >= 50 mL/min/1.73m^2 (normalized to BSA) for patients with creatinine levels greater than 1.5 times the institutional normal creatinine =< 1.5 X ULN or creatinine clearance >= 50ml/min/1.73m^2 (obtained within 2 weeks prior to registration to Step 2)
-
STEP 2 (CROSSOVER ARM Z): Patient must have corrected QT interval calculated by the Fridericia formula (QTcF) =< 500 ms within 28 days prior to Step 2 registration
-
STEP 2 (CROSSOVER ARM Z): Patient must not have any intercurrent illness or disease complication that the investigator believes would limit the ability to safely tolerate the combination of cabozantinib and nivolumab
-
STEP 2 (CROSSOVER ARM Z): Patient must not be pregnant or breast-feeding due to the unknown effects of cabozantinib and nivolumab on human development and for the potential risk for adverse events in nursing infants with the treatment regimens being used.
- All patients of childbearing potential must have a blood test or urine study within 14 days prior to registration to Step 2 to rule out pregnancy.
- A patient of childbearing potential is anyone, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months).
-
STEP 2 (CROSSOVER ARM Z): Patients must not expect to conceive or father children by using accepted and effective method(s) of contraception or by abstaining from sexual intercourse for the duration of their participation in the study and for 6 months after completion of treatment on the study
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Step 1, Arm A (cabozantinib S-malate)
Patients in Step 1, Arm A receive cabozantinib S-malate PO QD. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients may continue to receive therapy after investigator-assessed RECIST 1.1 defined progression, including stable clinical and performance status and have potential for continued clinical benefit. Patients also undergo ECHO as clinically indicated, CT throughout the trial, and collection of blood on study. |
Undergo CT
Andre navn:
Given PO
Andre navn:
Undergo ECHO
Andre navn:
Undergo blood collection
Andre navn:
|
|
Eksperimentell: Step 1, Arm B (cabozantinib S-malate, nivolumab)
Patients in Step 1, Arm B receive cabozantinib S-malate PO QD and nivolumab IV over 30 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients may continue to receive therapy after investigator-assessed RECIST 1.1 defined progression, including stable clinical and performance status and have potential for continued clinical benefit. Patients also undergo ECHO as clinically indicated, CT throughout the trial, and collection of blood on study. |
Undergo CT
Andre navn:
Given PO
Andre navn:
Undergo ECHO
Andre navn:
Given IV
Andre navn:
Undergo blood collection
Andre navn:
|
|
Aktiv komparator: Step 1, Arm C (standard chemotherapy)
Patients in Step 1, Arm C receive ramucirumab IV over 30-60 minutes and docetaxel IV over 1 hour on day 1, or docetaxel IV over 1 hour on days 1 and 8, or gemcitabine hydrochloride IV on days 1 and 8, or paclitaxel IV over 3 hours on day 1, or nab-paclitaxel IV over 30 minutes on days 1 and 8. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity and at the discretion of the treating physician. Patients also undergo ECHO as clinically indicated, CT throughout the trial, and collection of blood on study. |
Given IV
Andre navn:
Given IV
Andre navn:
Undergo CT
Andre navn:
Undergo ECHO
Andre navn:
Undergo blood collection
Andre navn:
Given IV
Andre navn:
Given PO
Andre navn:
Given IV
Andre navn:
|
|
Eksperimentell: Step 2, Arm Z (cabozantinib S-malate, nivolumab)
Patients in Step 2, Arm Z receive cabozantinib S-malate PO QD and nivolumab IV over 30 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients may continue to receive therapy after investigator-assessed RECIST 1.1 defined progression, including stable clinical and performance status and have potential for continued clinical benefit. Patients also undergo ECHO as clinically indicated, CT throughout the trial, and collection of blood on study. |
Undergo CT
Andre navn:
Given PO
Andre navn:
Undergo ECHO
Andre navn:
Given IV
Andre navn:
Undergo blood collection
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Progression-free survival (PFS) for patient population with non-squamous no-small cell lung cancer (NSCLC)
Tidsramme: After 58 events (From time of randomization to documented disease progression [site review of imaging] or death from any cause, whichever occurs first)
|
The final analysis of PFS will be performed when the full information of PFS is reached (i.e., 58 events for each of the two primary comparisons). The two primary comparisons of PFS will each use a logrank test stratified on the randomization stratification factors with a one-sided type I error rate of 10%. Estimates of PFS including medians and confidence intervals, will be calculated using the Kaplan-Meier method. Cox proportional hazards models, stratified, on the same factors, will be used to estimate the treatment hazard ratios. At the final analyses, in the event that both primary PFS comparisons of the combination of nivolumab with cabozantinib and cabozantinib alone versus the standard chemotherapy are statistically significant, PFS will be compared between the two experimental arms (combination of nivolumab with cabozantinib versus [vs.] cabozantinib alone), using a stratified log rank test with a one-sided type I error rate of 10%. |
After 58 events (From time of randomization to documented disease progression [site review of imaging] or death from any cause, whichever occurs first)
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Overall survival (OS) for each arm
Tidsramme: From time of randomization to documented disease progression (site review of imaging) or death from any cause, whichever occurs first, assessed up to 3 years
|
The final analysis of OS will be performed when the full information of PFS is reached (i.e., 58 events for each of the two primary comparisons). OS will be tested in a hierarchical fashion if the primary comparison of PFS between treatment arms is statistically significant, using a log rank test stratified on the randomization stratification factors with a one-sided type I error rate of 10%. Estimates of OS, including medians and confidence intervals, will be calculated using the Kaplan-Meier method. Cox proportional hazards models, stratified, on the same factors, will be used to estimate the treatment hazard ratios. OS will be further tested in a hierarchical fashion if the comparison of PFS between the two experimental arms is statistically significant. Point estimates of all endpoints will be accompanied by the corresponding two-sided 80% confidence intervals. Subset analyses of PFS and OS by treatment arm will be estimated and compared within subsets. |
From time of randomization to documented disease progression (site review of imaging) or death from any cause, whichever occurs first, assessed up to 3 years
|
|
Best objective response for each arm
Tidsramme: Every 6 weeks for the first year on study, and then every 12 weeks after year one
|
Will be evaluated via Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria. Response rates (complete response [CR] + partial response [PR]) and toxicity will be compared using Fisher's exact tests with a one-sided type I error rate of 10%; multivariable logistic regression modeling will be used to adjust for the effect of any covariates that are associated with these categorical outcomes. Modeling procedures will implement backward selection; variables significant at the 0.10 level in the univariate setting will be chosen for inclusion in an initial full model, and at each step the least significant variable will be removed from the model. Only those covariates with p < 0.05 will remain in any final models, unless there are factors identified by the study team as crucial to model interpretation. Point estimates of all endpoints will be accompanied by the corresponding two-sided 80% confidence intervals. |
Every 6 weeks for the first year on study, and then every 12 weeks after year one
|
|
Toxicity profile of monotherapy with cabozantinib, and the combination of nivolumab and cabozantinib
Tidsramme: Up to 3 years after completion of study treatment
|
Will be determined using the Common Terminology Criteria for Adverse Events (CTCAE) criteria. Response rates (complete response [CR] + pathologic response [PR]) and toxicity will be compared using Fisher's exact tests with a one-sided type I error rate of 10%; multivariable logistic regression modeling will be used to adjust for the effect of any covariates that are associated with these categorical outcomes. Modeling procedures will implement backward selection; variables significant at the 0.10 level in the univariate setting will be chosen for inclusion in an initial full model, and at each step the least significant variable will be removed from the model. Only those covariates with p < 0.05 will remain in any final models, unless there are factors identified by the study team as crucial to model interpretation. Point estimates of all endpoints will be accompanied by the corresponding two-sided 80% confidence intervals. |
Up to 3 years after completion of study treatment
|
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
The RECIST1.1 response at each time point
Tidsramme: Every 6 weeks for the first year on study, and then every 12 weeks after year one
|
The measurement of each time point will be performed using the revised CHOI criteria will be only applied to arms A and B, which will include anti-angiogenic therapy. Both the RECIST1.1 and revised CHOI criteria will assess the overall best response as CR, partial PR, stable disease (SD), or progressive disease (PD). Their concordance will be assessed using the weighted Cohen's kappa coefficient (k) with quadratic weights. As a rule of thumb, the level of concordance between the two criteria will be considered poor (k <0), slight (k 0-0.20), fair (k 0.21-0.40), moderate (k 0.41-0.60), substantial (k 0.61-0.80), and almost perfect (k 0.81 - 1). |
Every 6 weeks for the first year on study, and then every 12 weeks after year one
|
|
Agreement between central view and site review in terms of progression-free survival
Tidsramme: After the completion of study treatment
|
The progression status and the progression time will be assessed in agreement. The progression status is a binary measurement and the agreement will be assessed using the Cohen's kappa coefficient. For progression time, will assess the temporal agreement using the method developed by Zeng et al. |
After the completion of study treatment
|
|
Correlative biomarker research
Tidsramme: After the completion of study treatment
|
Correlative biomarker research will be performed on tissue and blood specimens collected within this trial. |
After the completion of study treatment
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Joel W Neal, ECOG-ACRIN Cancer Research Group
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Neoplasmer etter nettsted
- Neoplasmer
- Sykdommer i luftveiene
- Lungesykdommer
- Neoplasmer i luftveiene
- Thoracale neoplasmer
- Lungeneoplasmer
- Aminosyrer, peptider og proteiner
- Proteiner
- Organiske kjemikalier
- Heterocykliske forbindelser, 1-ring
- Heterocykliske forbindelser
- Undersøkelsesteknikker
- Kliniske laboratorieteknikker
- Diagnostiske teknikker og prosedyrer
- Diagnose
- Hydrokarboner
- Cycloparaffins
- Hydrokarboner, alicyklisk
- Hydrokarboner, syklisk
- Terpener
- Antistoffer, monoklonalt, humanisert
- Antistoffer, monoklonalt
- Antistoffer
- Immunoglobuliner
- Immunoproteiner
- Blodproteiner
- Serumglobuliner
- Globuliner
- Taxoider
- Cyclodecanes
- Diterpenes
- Deoxycytidine
- Cytidin
- Pyrimidin -nukleosider
- Pyrimidiner
- Helsevesenets økonomi og organisasjoner
- Albuminer
- Økonomi
- Docetaxel
- Nivolumab
- Albuminbundet paklitaksel
- Gemcitabin
- Ramucirumab
- Paclitaxel
- Prøvehåndtering
- 130-nm albuminbundet paclitaxel
- Cabozantinib
- Skatter
Andre studie-ID-numre
- NCI-2020-01541
- U10CA180820 (U.S. NIH-stipend/kontrakt)
- NCI-2020-01541 (Registeridentifikator: CTRP (Clinical Trial Reporting Program))
- EA5191 (Annen identifikator: CTEP)
- EA5191 (Annen identifikator: ECOG-ACRIN Cancer Research Group)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .